Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOSNASDAQ:KMDANASDAQ:RVNCNASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$0.74-1.8%$0.70$0.55▼$1.81$95.95M1.46823,468 shs439,886 shsKMDAKamada$6.64-0.7%$6.69$4.74▼$9.16$381.67M1.0785,589 shs52,010 shsRVNCRevance Therapeutics$3.65$3.65$2.30▼$6.65$381.02M0.93.24 million shsN/ATECXTectonic Therapeutic$20.18-4.3%$20.81$13.70▼$61.07$376.62M2.87173,982 shs134,124 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics-1.77%+16.68%+6.69%-15.09%-51.45%KMDAKamada-0.75%+3.75%-1.63%-3.21%+28.93%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%+7.35%TECXTectonic Therapeutic-4.31%+12.61%+8.20%-17.43%+2,017,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics1.9803 of 5 stars3.52.00.00.02.61.70.0KMDAKamada3.8609 of 5 stars3.55.00.00.02.21.72.5RVNCRevance Therapeutics2.1184 of 5 stars3.10.00.04.70.61.70.6TECXTectonic Therapeutic2.534 of 5 stars3.61.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics 3.00Buy$7.13859.21% UpsideKMDAKamada 3.00Buy$14.67120.88% UpsideRVNCRevance Therapeutics 2.11Hold$8.39129.75% UpsideTECXTectonic Therapeutic 3.14Buy$72.40258.77% UpsideCurrent Analyst Ratings BreakdownLatest ATOS, KMDA, RVNC, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ATOSAtossa TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.254/21/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$51.003/26/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/21/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/21/2025TECXTectonic TherapeuticWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$112.00 ➝ $101.003/12/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/6/2025KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.001/31/2025TECXTectonic TherapeuticWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$79.00 ➝ $112.001/30/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/AKMDAKamada$160.95M2.37$0.37 per share17.90$4.25 per share1.56RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11TECXTectonic TherapeuticN/AN/AN/AN/A$2.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.21N/AN/AN/AN/A-35.74%-33.51%5/12/2025 (Estimated)KMDAKamada$8.28M$0.2623.7120.750.979.92%6.30%4.49%5/6/2025 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%5/7/2025 (Estimated)TECXTectonic Therapeutic$12.16M-$6.53N/AN/AN/AN/A-35.53%-31.97%5/8/2025 (Estimated)Latest ATOS, KMDA, RVNC, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07N/AN/AN/A$154.06 millionN/A5/12/2025Q1 2025ATOSAtossa Therapeutics-$0.06N/AN/AN/AN/AN/A5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10N/AN/AN/AN/AN/A3/25/2025Q4 2024ATOSAtossa Therapeutics-$0.0633-$0.05+$0.0133-$0.05N/AN/A3/20/2025Q4 2024TECXTectonic Therapeutic-$1.39-$0.84+$0.55-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ALatest ATOS, KMDA, RVNC, and TECX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2025KMDAKamada--$0.203/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A13.3013.30KMDAKamadaN/A4.842.73RVNCRevance TherapeuticsN/A4.123.05TECXTectonic TherapeuticN/A9.399.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%KMDAKamada20.38%RVNCRevance Therapeutics97.70%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.60%KMDAKamada36.10%RVNCRevance Therapeutics5.10%TECXTectonic Therapeutic9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics8129.17 million116.24 millionOptionableKMDAKamada36057.48 million36.73 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableTECXTectonic Therapeutic12018.66 million13.40 millionN/AATOS, KMDA, RVNC, and TECX HeadlinesRecent News About These CompaniesInvesco Ltd. Purchases New Stake in Tectonic Therapeutic (NASDAQ:TECX)April 28 at 3:35 AM | marketbeat.comWhy Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 7.37%April 26 at 7:54 PM | aaii.comAnalysts Set Tectonic Therapeutic (NASDAQ:TECX) Target Price at $77.75April 24, 2025 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at MizuhoApril 23, 2025 | marketbeat.comTectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEFApril 23, 2025 | seekingalpha.comTectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEFApril 23, 2025 | seekingalpha.comTectonic Therapeutic (NASDAQ:TECX) Short Interest UpdateApril 22, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Earns Outperform Rating from Analysts at MizuhoApril 22, 2025 | americanbankingnews.comTectonic Therapeutic initiated with an Outperform at MizuhoApril 21, 2025 | markets.businessinsider.comMizuho Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationApril 21, 2025 | msn.comTectonic Therapeutic (NASDAQ:TECX) Receives Average Rating of "Buy" from BrokeragesApril 21, 2025 | marketbeat.comTectonic Therapeutic (TECX) Receives Outperform Rating from Mizuho | TECX Stock NewsApril 21, 2025 | gurufocus.comVanguard Group Inc. Has $16.67 Million Position in Tectonic Therapeutic (NASDAQ:TECX)April 19, 2025 | marketbeat.comTectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025April 15, 2025 | markets.businessinsider.comTectonic Therapeutic (NASDAQ:TECX) Director Acquires $54,877.68 in StockApril 12, 2025 | insidertrades.comMajor Investment Alert: Insider Buys Big in Tectonic Therapeutic!April 11, 2025 | tipranks.comHedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, John Hempton, Ken Griffin, George Soros, Eisler Capital, Tectonic Therapeutic Inc (TECX), BigBear.ai Holdings Inc (BBAI), and MoreApril 10, 2025 | insidermonkey.comTectonic Therapeutic (NASDAQ:TECX) Director Acquires $1,496,250.00 in StockApril 10, 2025 | insidertrades.comMajor Investment Alert: Insider Buys Big in Tectonic Therapeutic!April 9, 2025 | tipranks.comTectonic Therapeutic (NASDAQ:TECX) Shares Sold by ADAR1 Capital Management LLCApril 9, 2025 | marketbeat.comDirector’s Bold Move: Massive Stock Sale Shakes Tectonic Therapeutic!April 7, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATOS, KMDA, RVNC, and TECX Company DescriptionsAtossa Therapeutics NASDAQ:ATOS$0.74 -0.01 (-1.77%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$0.74 0.00 (-0.51%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Kamada NASDAQ:KMDA$6.64 -0.05 (-0.75%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$6.66 +0.02 (+0.36%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Revance Therapeutics NASDAQ:RVNC$3.65 0.00 (0.00%) As of 02/6/2025Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Tectonic Therapeutic NASDAQ:TECX$20.18 -0.91 (-4.31%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$19.95 -0.23 (-1.11%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
